Lundbeck and Merck sign exclusive commercialisation agreement for SYCREST (asenapine) sublingual tablets
Lundbeck expects to launch SYCREST in the EU at the beginning of 2011
14-Oct-2010
- USA
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.